One of the ATC concurrent sessions was dedicated to novel immunosuppressants.  Here is a brief breakdown of the session. Dr. Muhbacher presented Phase 1 results of a novel [...]

The new kidney allocation system (KAS) began December 2014.  As previously blogged, key strategic goals of the KAS include more equity for highly sensitized patients, [...]

Highly sensitized patients are among the most difficult to transplant and are plagued by early rejection and graft loss.  Currently, most immunosuppressive agents are [...]

The investigators of the SIMCER study set out to answer this very question.  The incidence of stage 4 CKD 5 years after kidney transplant ranges from 7-21%.  Up to 60% of [...]

The American Transplant Congress (ATC) is the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.  This year [...]